Hims & Hers Health's stock dropped 25% due to Amazon’s competition. Learn why HIM stock's 38% upside and strong growth make ...

The company's revenue jumped 77% in Q3 to reach $401.6 million in Q3 2024, alongside a net income of $75.6 million. It now ...

The expanded services help customers receive consultations and medications for erectile dysfunction, men’s hair loss, eyelash growth, motion sickness, and anti-aging skin care.

Amazon announced Prime members can access new upfront pricing for treatment of five common conditions such as erectile ...

Fintel reports that on November 14, 2024, B of A Securities downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from ...

Citi analyst Daniel Grosslight has maintained their neutral stance on HIMS stock, giving a Hold rating on November 6. Daniel ...

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

Shares of vaccine makers fell on reports that President-elect Donald Trump is expected to nominate Robert F. Kennedy Jr., a ...

Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.’s latest push into healthcare will ...

Shares of Hims & Hers (HIMS) are sliding on Thursday after Amazon (AMZN) announced the launch of its Amazon One Medical Pay-per-visit ...

Hims & Hers, founded in 2017 as “Hims,” started as a platform ... It has since expanded to include treatments for both men ...

Canada's main stock index touched a record high on Thursday, helped by energy stocks, while investors digested a mixed batch of U.S. economic data and awaited Federal Reserve Chair Jerome Powell's ...